Literature DB >> 6743386

Effect of atenolol on plasma HDL cholesterol subfractions.

A Lehtonen, J Marniemi.   

Abstract

The effect of atenolol on plasma HDL cholesterol subfractions and other plasma lipids in 18 patients with essential hypertension was studied. The atenolol was given orally, in a dose of 100 mg once daily for 6 months. The level of HDL cholesterol during atenolol treatment was significantly lower than before it. The concentration of HDL2 cholesterol decreased (P less than 0.01) during the first month of therapy and remained constant during treatment. The level of HDL3 cholesterol decreased slightly but not significantly. The concentrations of plasma triglycerides and total cholesterol increased slightly during atenolol treatment; statistical significance was reached (P less than 0.05) at 6 months.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743386     DOI: 10.1016/0021-9150(84)90181-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.

Authors:  M Ligueros; R Unwin; M R Wilkins; J Humphreys; S J Coles; J Cleland
Journal:  Clin Auton Res       Date:  1992-12       Impact factor: 4.435

Review 2.  The effects of diuretics and adrenergic-blocking agents on plasma lipids.

Authors:  J J Rohlfing; J D Brunzell
Journal:  West J Med       Date:  1986-08

Review 3.  The effect of exercise on lipid metabolism in men and women.

Authors:  L Goldberg; D L Elliot
Journal:  Sports Med       Date:  1987 Sep-Oct       Impact factor: 11.136

4.  Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.

Authors:  A Lehtonen; P Himanen; M Saraste; K Niittymäki; J Marniemi
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

5.  Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients.

Authors:  A Lehtonen
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

6.  Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol.

Authors:  M Välimäki; L Maass; K Harno; E A Nikkilä
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.

Authors:  Caitrin W McDonough; Nancy K Gillis; Abdullah Alsultan; Shin-Wen Chang; Marina Kawaguchi-Suzuki; Jason E Lang; Mohamed Hossam A Shahin; Thomas W Buford; Nihal M El Rouby; Ana C C Sá; Taimour Y Langaee; John G Gums; Arlene B Chapman; Rhonda M Cooper-DeHoff; Stephen T Turner; Yan Gong; Julie A Johnson
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.